JP2009507758A5 - - Google Patents

Download PDF

Info

Publication number
JP2009507758A5
JP2009507758A5 JP2008511498A JP2008511498A JP2009507758A5 JP 2009507758 A5 JP2009507758 A5 JP 2009507758A5 JP 2008511498 A JP2008511498 A JP 2008511498A JP 2008511498 A JP2008511498 A JP 2008511498A JP 2009507758 A5 JP2009507758 A5 JP 2009507758A5
Authority
JP
Japan
Prior art keywords
substituted
hydrogen
unsubstituted
alkyl
unsubstituted lower
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008511498A
Other languages
English (en)
Japanese (ja)
Other versions
JP5066516B2 (ja
JP2009507758A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2006/317691 external-priority patent/WO2007026950A1/en
Publication of JP2009507758A publication Critical patent/JP2009507758A/ja
Publication of JP2009507758A5 publication Critical patent/JP2009507758A5/ja
Application granted granted Critical
Publication of JP5066516B2 publication Critical patent/JP5066516B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008511498A 2005-09-01 2006-08-31 疼痛の治療に用いられるピリダジノン誘導体 Expired - Fee Related JP5066516B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71282505P 2005-09-01 2005-09-01
US60/712,825 2005-09-01
PCT/JP2006/317691 WO2007026950A1 (en) 2005-09-01 2006-08-31 Pyridazinone derivatives used for the treatment of pain

Publications (3)

Publication Number Publication Date
JP2009507758A JP2009507758A (ja) 2009-02-26
JP2009507758A5 true JP2009507758A5 (https=) 2012-08-30
JP5066516B2 JP5066516B2 (ja) 2012-11-07

Family

ID=37607561

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008511498A Expired - Fee Related JP5066516B2 (ja) 2005-09-01 2006-08-31 疼痛の治療に用いられるピリダジノン誘導体

Country Status (13)

Country Link
US (1) US20090042856A1 (https=)
EP (1) EP1919919A1 (https=)
JP (1) JP5066516B2 (https=)
KR (1) KR20080049758A (https=)
CN (1) CN101268079B (https=)
AU (1) AU2006285599A1 (https=)
BR (1) BRPI0617100A2 (https=)
CA (1) CA2620740A1 (https=)
IL (1) IL189697A0 (https=)
NO (1) NO20081572L (https=)
RU (1) RU2008112290A (https=)
TW (1) TW200745034A (https=)
WO (1) WO2007026950A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904421A (en) 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
EP2614053B1 (en) * 2010-09-08 2016-03-23 Sumitomo Chemical Company Limited Method for producing pyridazinone compounds and intermediates thereof
CN104039785A (zh) 2011-10-06 2014-09-10 拜耳知识产权有限责任公司 作为杀真菌剂的杂环基吡(嘧)啶基吡唑
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
HRP20170217T1 (hr) 2013-04-25 2017-04-21 Beigene, Ltd. Fuzinirani heterociklički spojevi kao inhibitori protein kinaze
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
CN106146404B (zh) * 2015-04-15 2020-03-20 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
CA3033827A1 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
CR20190157A (es) 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
EP3612522A4 (en) 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
TW202515616A (zh) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
WO2020249001A1 (zh) 2019-06-10 2020-12-17 百济神州瑞士有限责任公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
WO2000069464A1 (en) * 1999-05-12 2000-11-23 Fujisawa Pharmaceutical Co., Ltd. Novel use
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors

Similar Documents

Publication Publication Date Title
JP2009507758A5 (https=)
JP2025535046A (ja) Kras g12c変異タンパク質の複素環阻害剤及びその使用
JP6435323B2 (ja) 炎症性障害の治療のための新規化合物及びその医薬組成物
JP2019514878A5 (https=)
EP2552907B1 (en) Pyridyltriazoles
JP2012501312A5 (https=)
JP2009538896A5 (https=)
RU2012152548A (ru) Пиридоновые и азапиридоновые соединения и способы применения
RU2012136643A (ru) [5,6]- гетероциклическое соединение
JP2021506816A5 (https=)
JP2014522855A5 (https=)
ME02203B (me) Hinolin i hinoksalin derivati kao inhibitori kinaza
JP2003531210A5 (https=)
JP2019523233A5 (https=)
RU2018147424A (ru) Новые (гетеро)арил-замещенные пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
JP2011500774A5 (https=)
ME01290B (me) Piradizinski derivati kao smo inhibitori
HRP20180080T1 (hr) Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze
JP2011506466A5 (https=)
RU2006134021A (ru) Производные гетероарил-конденсированного пиразола
JP2013526536A5 (https=)
HRP20120105T1 (hr) Aminoheterociklički spojevi
CA2642922A1 (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
RU2008136784A (ru) Пиразолохинолоновые соединения, фармацевтическая композиция на их основе, способ ингибирования поли(адф-рибоза)полимеразы (parp) и способы лечения воспаления, сепсиса, септического шока и рака
EP2807166A1 (en) 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h]quinazolines as igf-lr/lr inhibitors